Skip to main content
. 2020 Aug 7;12:7043–7059. doi: 10.2147/CMAR.S252772

Figure 9.

Figure 9

Effect on the migration and invasiveness capability of glioma cells after treatment with the MAPK signaling pathway inhibitor PD325901, pcDNA3.1-IRAK3, and 5-aza-dC. (A and B) The migration capability was significantly lower in the PD325901, pcDNA3.1-IRAK3, and 5-aza-dC groups than in the control group. (A and C) The invasiveness capability was significantly lower in the PD325901, pcDNA3.1-IRAK3, and 5-aza-dC groups than in the control group. All the mentioned differences were significant (**P < 0.01).